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Summary
 
Gene expression patterns can provide vital clues to the pathogenesis of neoplastic diseases. We
investigated the expression of 950 genes in Hodgkin’s disease (HD) by analyzing differential
mRNA expression using microarrays. In two independent microarray experiments, the HD-
derived cell lines L428 and KMH2 were compared with an Epstein-Barr virus (EBV)-immor-
talized lymphoblastoid B cell line, LCL-GK. Interleukin (IL)-13 and IL-5 were found to be
highly expressed in the HD-derived cell lines. Examination of IL-13 and IL-5 expression by
Northern blot analysis and enzyme-linked immunosorbent assay confirmed these results and
revealed the expression of IL-13 in a third HD-derived cell line, HDLM2. Control LCL and
EBV-negative non-Hodgkin lymphoma–derived cell lines did not express IL-13. In situ hy-
bridization of lymph node tissue from HD patients showed that elevated levels of IL-13 were
specifically expressed by Hodgkin/Reed-Sternberg (H/RS) tumor cells. Treatment of a HD-
derived cell line with a neutralizing antibody to IL-13 resulted in a dose-dependent inhibition
of H/RS cell proliferation. These data suggest that H/RS cells produce IL-13 and that IL-13
plays an important role in the stimulation of H/RS cell growth, possibly by an autocrine mech-
anism. Modulation of the IL-13 signaling pathway may be a logical objective for future thera-
peutic strategies.
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H
 
odgkin’s disease (HD)
 
1
 
 is unique among human lym-
phoma in that the tumor cells, known as Hodgkin/
Reed-Sternberg (H/RS) cells, are exceedingly rare. Inves-
tigation of H/RS cells has been impeded by their low fre-
quency (0.1–1%) within the lymphoma tissue (1–4). PCR-
based assays of DNA from single H/RS cells have revealed
rearranged immunoglobulin genes and somatic mutations,
suggesting that H/RS cells are clonal and may be derived
from germinal center B cells (5, 6). However, the precise
pathogenesis of HD remains to be determined.
Much evidence has accumulated that suggests that the
proliferation and survival of HD-derived cells is due to cy-
tokine signaling. It is well established that the unique his-
tology and eosinophilia of HD tissues, as well as secondary
symptoms in the patient such as fever, weight loss, and night
sweats, are induced by a pathological pattern of cytokine
secretion (1, 2). However, it has not been possible to con-
sistently demonstrate the overexpression of a particular cyto-
kine or group of cytokines in all HD-derived cell lines and
primary H/RS tumor cells. Thus, the identity of particular
cytokines playing a role in the pathogenesis of HD remains
rather controversial.
The tool of microarray analysis has recently been devel-
oped (7–9) as a very efficient means of studying the differ-
ential expression of many genes simultaneously. Gene expres-
sion in two different samples is compared using competitive
hybridization of two probes labeled with different fluores-
cent dyes. We have used microarrays containing 950 cDNA
segments from genes relevant to inflammation and neoplasia
to investigate gene expression patterns in HD-derived cell
lines. Microarray expression patterns in the aneuploid,
clonal cell lines L428 and KMH2 (2), which were cultured
from Hodgkin tissues and are regarded as HD cell lines,
 
1
 
Abbreviations used in this paper:
 
 HD, Hodgkin’s disease; H/RS, Hodgkin/
Reed-Sternberg; NHL, non-Hodgkin lymphoma. 
1940
 
IL-13 Stimulates Growth of Reed-Sternberg Cells
 
were compared with microarray expression patterns in a
control EBV-infected lymphoblastoid B cell line LCL-GK,
which was derived from a healthy individual. Of the 950
genes on the microarray, IL-5 and IL-13 were the most
strongly differentially expressed in both HD-derived cell
lines, but only IL-13 was consistently overexpressed in a third
HD cell line and primary H/RS tumor cells examined.
Moreover, functional analysis revealed a role for IL-13 in
stimulating the proliferation of H/RS cells.
Our study strongly suggests that IL-13 is a crucial factor
in the pathogenesis of HD, and demonstrates the utility of
cDNA microarray analysis of gene expression patterns in
unraveling the complexities underlying neoplastic diseases
like HD.
 
Materials and Methods
 
Cell Culture.
 
The cell lines were grown in IMDM medium
supplemented with penicillin, streptomycin, and 10% FCS. The
cell lines HDLM2 and LCL-HO were purchased from the Ger-
man Collection of Microorganisms and Cell Cultures. The cell
line LCL-GK was a gift from Dr. M. Dosch (Hospital for Sick
Children, Toronto, Ontario, Canada), and the EBV-negative non-
Hodgkin lymphoma (NHL)-derived cell lines Ly4, Ly7 and
Ly13.2 were provided by Dr. H. Messner (Ontario Cancer Insti-
tute/Princess Margaret Hospital, Toronto, Ontario, Canada).
 
Microarray Experiments.
 
Polyadenylated [poly(A)
 
1
 
] mRNA
was prepared from total RNA on Oligotex-dT resin (Qiagen).
Each mRNA sample was converted into fluorescent-labeled cDNA
probes using the microarray (GEM) probe labeling kit (Synteni).
The microarray used in these experiments contained 950 human
genes involved in inflammation and neoplasia (Synteni). Two
microarrays were independently probed with 200 ng of a 1:1
mixture of fluorescein-labeled cDNA from HD-derived L428
cells and control LCL-GK cells on Microarray 1 (M1) or from
HD-derived KMH2 cells and LCL-GK cells on microarray 2 (M2),
respectively. Known concentrations of mRNA synthesized from
inter–open reading frame regions from 
 
Saccharomyces cerevisiae
 
 were
used as quantitation standards. The hybridization was performed
as previously described (7).
 
Northern Blot Analysis.
 
Total RNA was isolated using Trizol
reagent (GIBCO BRL). 15 
 
m
 
g total RNA was separated on a 1%
formaldehyde agarose gel. Samples were run in 0.02 M MOPS
(3-[N-morpholino]propanesulfonic acid), pH 7.0, 8 mM sodium ac-
etate, 1 mM EDTA. The gel was blotted overnight in 20
 
3
 
 SSC on
a Hybond N
 
1
 
 nylon membrane (Amersham Pharmacia Biotech)
and cross-linked using UV irradiation. Membranes were hybridized
at 65
 
8
 
C to [
 
a
 
-
 
32
 
P]dATP-labeled (Mutiprime DNA Labeling System,
Amersham Pharmacia Biotech) cDNA fragments specific for the hu-
man Notch2, NF-IL3, urokinase, IL-13, and human 
 
b
 
-actin genes.
Membranes were washed first in 0.1% SDS/2
 
3
 
 SSC (30 min, 65
 
8
 
C)
and then in 0.1% SDS/0.2
 
3
 
 SSC (30 min, 65
 
8
 
C).
 
Cytokine Production.
 
Supernatants of cell cultures (10
 
5
 
 cells/ml)
were recovered 48 h after medium exchange and assayed for
IL-5, IL-13, and GM-CSF production by specific ELISA using
Quantikine-kits (R&D Systems).
 
Fixation of Biopsied Material.
 
Freshly biopsied lymph nodes were
fixed in 10% formalin for 24 h before overnight processing and
paraffin embedding.
 
In Situ Hybridization.
 
For in situ hybridization, paraffin sec-
tions were mounted and fixed according to standard protocols.
 
The IL-13 probe used was a 388-bp human cDNA probe synthe-
sized using reverse transcriptase PCR and IL-13–specific primers
as follows: 5
 
9
 
 GTTGACCACGGTCATTGCTCTCACT and 3
 
9
 
TTCAGTTGAACCGTCCCTCGCGAA. The cDNA was cloned
into the pCRII vector (TA Cloning Kit; Invitrogen). Sense and
antisense probes were synthesized from the linearized vector with
SP6 or T7 polymerase, labeled with [
 
33
 
P]UTP, and processed as
previously described (10). The sections were counterstained with
toluidine blue using a standard protocol.
 
Immunohistochemistry.
 
Immunohistochemistry was performed
using mAbs against CD30 (Dako) and CD15 (Becton Dickinson).
Formalin-fixed paraffin sections were digested with pepsin and
incubated (1 h) with the primary antibody. The slides were
washed in PBS and incubated with biotinylated rabbit anti–
mouse IgG (20 min) and with streptavidin–biotin complex labeled
with horseradish peroxidase (20 min) after a second washing step
(Ultra Streptavidin Detection System; Signet). The enzyme reac-
tion was developed with AEC (3-amino-9-ethyl carbazole) and
the slides were counterstained with hematoxylin.
 
Analysis of Cell Proliferation after Neutralization of IL-13.
 
HD-
derived L428, KMH2, and HDLM2 cells and LCL control cells
(2 
 
3
 
 10
 
4
 
/well) were cultured in 96-well flat-bottomed plates for
24, 48, or 72 h in the presence of anti–IL-13, anti–IL-5, or iso-
type control antibodies (PharMingen) at 5, 10, 20, 30, 50, 100, or
150 
 
m
 
g/ml. Cells were treated either with 0.5, 1, 5, 10, 50, 100,
and 200 ng/ml IL-13 (R&D Systems) or with these doses of
IL-13 combined with 20 
 
m
 
g/ml anti–IL-13. [
 
3
 
H]thymidine (1 
 
m
 
Ci/
well) was added to each well for an 8-h incubation. The cells
were harvested on filters and the incorporation of [
 
3
 
H]thymidine
into cellular DNA was measured as previously described (11).
 
Results and Discussion
 
Of 950 genes displayed on the microchip, the genes
showing a greater than threefold difference in expression in
both HD-derived cell lines were IL-13; IL-5; ornithine de-
carboxylase (ODC); ICAM-3; urokinase plasminogen acti-
vator (UPA); IgE Fc receptor II; insulin-like growth factor
(IGF) II; NF-IL3/E4BP4; Notch2; GM-CSF; interferon
regulatory factor (IRF)-1, IRF-5, and IRF-6; nitric oxide
synthase (NOS) 3; and the TCR 
 
d
 
 chain (Fig. 1 B). IL-13
expression in HD-derived L428 and KMH2 cells was in-
creased compared with that in control LCL-GK cells by
26.7- and 17.1-fold, respectively, and IL-5 expression was
increased by 14.2- and 18.5-fold (Fig. 1 B).
To evaluate the significance of these results, we used
Northern blots and ELISA to compare the expression of
IL-13, IL-5, GM-CSF, NF-IL3, Notch2, and urokinase in
the HD-derived EBV-negative cell lines L428, KMH2,
and HDLM2 (2) with that in the lymphoblastoid EBV-
infected B cell lines LCL-GK and LCL-HO, and in three
EBV-negative NHL-derived cell lines with either B cell
(Ly4, Ly7) or T cell (Ly13.2) phenotype. Notch2, uroki-
nase, and NF-IL3 were upregulated in LCL or NHL cell
lines as well as in the HD-derived cell lines, but the over-
expression of IL-13, IL-5, and GM-CSF was restricted to
the HD-derived cell lines (Fig. 2). Although IL-5 and
GM-CSF expression and secretion could be demonstrated
only in L428 and KMH2 cells, mRNA expression and se-
cretion of IL-13 could be detected in all three HD-derived 
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cell lines. HDLM2 cells secreted a moderate amount of IL-13
(27 pg/ml), whereas L428 and KMH2 cells demonstrated
intense IL-13 (4,800 and 6,100 pg/ml, respectively) secre-
tion (Fig. 2 B).
To confirm that IL-13 was expressed by the H/RS tu-
mor cells, in situ hybridization using sense and antisense RNA
probes for IL-13 was performed on lymph node biopsies
from four untreated patients newly diagnosed with classical
nodular sclerosis HD. The diagnosis was based on the nod-
ular sclerosis architecture of the lymph nodes, the presence
of H/RS cells in the appropriate context, and the immuno-
histological detection of CD30 and CD15 expression by
cells with H/RS morphology. In all four patients, signifi-
cant numbers of cells expressing IL-13 were detected (Fig.
3 A). Virtually all IL-13–expressing cells displayed morpho-
logical features of H/RS cells such as large size, prominent
nucleoli, and multinuclear and/or lacunar cell morphology.
Also, some IL-13–expressing cells were mitotic (Fig. 3 B).
To test whether cells with a positive signal for expression of
IL-13 express the HD markers CD30 and CD15, serial sec-
Figure 1. Differential expres-
sion of 950 genes investigated by
microarray hybridization. (A)
Genes showing the greatest dif-
ferential expression are indicated.
The vertical axis shows differen-
tial expression calculated as the
ratio of the values of the two
channels recording Fluorescence1
signal (Cy3) and Fluorescence2
signal (Cy5). A positive number
indicates that Cy3 (channel one)
is greater than Cy5 (channel
two), whereas a negative number
indicates that Cy5 is greater than
Cy3. (B) Genes showing differ-
ences in expression that were
greater than threefold on two
microarrays (M1, M2). Fluores-
cent scans are represented in
pseudocolor and correspond to
hybridization intensities of genes.
False colors ranging from black
(at the low end) through blue,
green, yellow, and red to white
(at the high end) indicate the in-
tensity of the signal. E3, retinoic
acid-inducible E3 protein; IGFII,
insulin-like growth factor II;
IRF, interferon regulatory fac-
tor; NOS 3, nitric oxide synthase
3; ODC, ornithine decarboxy-
lase; UPA, urokinase plasmino-
gen activator.
Figure 2. Differential expression of se-
lected genes in HD-derived cell lines and
control LCL and NHL-derived cell lines.
(A) Northern blot analysis of total RNA
from the EBV-negative, HD-derived cell
lines L428, KMH2, and HDLM2; the EBV-
immortalized lymphoblastoid B cell lines
LCL-GK and LCL-HO; and the EBV-neg-
ative NHL-derived cell lines Ly4, Ly7, and
Ly13.2. (B) Immunoassays to detect human
IL-13, IL-5, and GM-CSF produced by the
cell lines in A. 
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tions from two patients were cut and stained by immuno-
histochemistry for CD30 or CD15, or used for in situ hy-
bridization with an IL-13 antisense probe. On these serial
sections, it was possible to correlate a high proportion of
IL-13 mRNA–containing cells with the presence of CD30
and CD15 expression by the same tumor cell (Fig. 3, C–E).
A benign reactive lymph node hybridized in parallel with
the IL-13 probe as well as a lymph node from a HD patient
hybridized with an IL-13 sense probe did not yield any sig-
nal (data not shown), illustrating the specificity of IL-13 ex-
pression by H/RS cells in lymph nodes from HD patients.
To investigate the effects of IL-13 and IL-5 on the pro-
liferation of H/RS cells, L428, KMH2, and HDLM2 cells
were incubated with medium alone, medium containing
neutralizing antibodies to IL-13 or IL-5, or isotype controls.
Proliferation was measured by determining [
 
3
 
H]thymidine
incorporation at 24, 48, or 72 h after treatment. The viabil-
ity of cultured cell lines after treatment with anti–IL-13
neutralizing antibodies was examined by 7-aminoactino-
mycin D (7-AAD) staining; no significant differences be-
tween HD-derived cells and controls were detected (data
not shown). Neutralizing antibodies against IL-13 and IL-5
had no effect on the proliferation of control LCL-HO cells
(Fig. 4, A and B). However, after 72 h of treatment with
20 
 
m
 
g/ml anti–IL-13 neutralizing antibody, the prolifera-
tion of HDLM2 cells (which secrete moderate levels of
IL-13) was suppressed to 27% of that of untreated control
cells (Fig. 4 A). Treatment of L428 and KMH2 cells with
 
#
 
150 
 
m
 
g/ml anti–IL-13 antibody had no effect on the
proliferation of the cell lines (data not shown), perhaps be-
cause of their vigorous secretion of IL-13 (Fig. 2). No sig-
nificant changes in proliferation were observed in control
groups of HDLM2 cells treated with an anti–IL-5 neutral-
izing antibody (Fig. 4 B) or isotype control antibodies (Fig.
4 C). A combination of anti–IL-13 and anti–IL-5 antibod-
ies did not inhibit proliferation to any greater extent than
anti–IL-13 alone (data not shown). Treatment with in-
creasing concentrations of anti–IL-13 antibody demon-
strated that the effect on the proliferation of HD-derived
cells was dose dependent (Fig. 4 D). Furthermore, the anti-
proliferative effect of anti–IL-13 on HDLM2 cells could be
overcome by the addition of exogenous IL-13 (Fig. 4 E).
Treatment of HDLM2 cells with exogenous IL-13 alone
did not result in an increase in proliferation over that of un-
treated cells (Fig. 4 F), suggesting that the cells produce sat-
urating levels of IL-13 sufficient to support maximal prolif-
eration.
The systemic symptoms of HD and the unique reactive
cellular background exhibited in HD biopsies suggest that
cytokines are involved in HD pathogenesis. The elevated
expression of various cytokines has been reported in HD
biopsies and several HD-derived cell lines (1, 2). Overex-
pression of IL-5 in H/RS cells has been demonstrated pre-
viously by in situ hybridization, but only in HD patients
exhibiting eosinophilia (12, 13). To date, no cytokine has
been consistently reported as being overexpressed in HD-
derived cell lines or in primary H/RS cells.
Of 950 genes tested, we found that only IL-13 was con-
sistently and specifically overexpressed in H/RS tumor
cells. IL-13 is a T cell–derived cytokine with immunomod-
Figure 3. IL-13 expression in the
lymph node of a patient with
Hodgkin’s disease. Paraffin sections
of the diagnostic formalin-fixed cer-
vical lymph node from a 53-yr-old
male patient with Hodgkin’s disease
of the nodular sclerosis subtype,
clinical stage IIA. (A, B, and D) In
situ hybridization for IL-13, black
silver grains denote IL-13 expres-
sion. (A) Multinuclear Reed-Stern-
berg and Hodgkin cells express
IL-13. (B) Mitotic H/RS cell with a
positive IL-13 signal. (C–E) Serial
sections were stained for CD30 (C)
or CD15 (E) or hybridized with an
IL-13 antisense probe (D). The pho-
tographs are taken from the same
area of three consecutive serial sec-
tions and illustrate the expression of
CD30, IL-13, and CD15 by the
same cell. Original magnification: A,
3400; B, 31,000; C–E, 3200. 
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ulatory and antiinflammatory properties (14). The biologi-
cal effects of IL-13 on B cells, macrophages, and monocytes
are very similar to those of IL-4, probably because the IL-4
and IL-13 receptors share a common 
 
a
 
 chain. In B cells,
IL-13 promotes proliferation, differentiation, and Ig heavy
chain class switching to IgE and IgG4 (15). Proliferation re-
sults from a signaling pathway in which the engagement of
the IL-13 receptor activates JAK1, which in turn activates
STAT6 (16). Our results suggest that a similar mechanism
may operate in the B cell–like H/RS cells, since neutraliza-
tion of IL-13 dramatically inhibited the proliferation of
HD-derived HDLM2 cells (Fig. 4 A). Indeed, in the mi-
croarray experiments, mRNA for the IL-13 receptor was
found to be expressed in both of the HD-derived cell lines
tested (data not shown). The secretion of IL-13 by H/RS
cells, the expression of mRNA for the IL-13 receptor, and
the specific effect of the neutralizing anti–IL-13 antibody
suggest that an autocrine mechanism may control the
growth of H/RS tumor cells.
Evidence for a role for IL-13 in the etiology of HD is in-
direct but consistent. IgE is elevated in HD tissues and se-
rum samples from HD patients (13, 17), and IL-13 is known
to promote Ig class switching to IgE. IL-13–deficient mice
exhibit lower basal levels of serum IgE (18). Furthermore,
studies of IL-4–deficient, IL-13–transgenic mice have dem-
onstrated that IL-13 can promote class switching to IgE in-
dependently of IL-4 (19), emphasizing that IL-4 and IL-13
have distinct roles in regulating B cell functions. Our results
have clearly demonstrated that HD-derived cell lines and
H/RS tumor cells express elevated levels of IL-13. The el-
evation of IgE in H/RS cells and in the serum of HD pa-
tients therefore could be explained if IL-13 secreted by
H/RS cells affects both the H/RS cells themselves and the
bystander B cells.
Other aspects of the HD phenotype may also be attribut-
able to the effects of IL-13. A recent study of IL-13–defi-
cient mice has shown that cultures of Th2 cells from these
animals produce significantly reduced levels of IL-4, IL-5,
and IL-10 compared with the results from the wild-type
animals, suggesting an important role for IL-13 as a regula-
tor of Th2 cell commitment (18). If IL-13 is also important
for promoting the differentiation of Th2 cells in humans, it
could explain why H/RS cells (which secrete IL-13) are
surrounded by Th2 cells in HD biopsies. In addition, be-
cause fibroblasts express the IL-13 receptor and can be acti-
vated by IL-13 (20), the secretion of IL-13 by H/RS cells
may underlie the pathogenesis of the fibrosis observed in
nodular sclerosis HD.
Our microarray hybridization also showed that the ex-
pression of NF-IL3 and Notch2 was upregulated by more
than threefold in HD-derived cell lines (Fig. 1). Northern
blot analysis revealed NF-IL3 and Notch2 expression also
in NHL-derived cell lines (Fig. 2 A). The basic leucine zip-
per transcription factor NF-IL3 acts downstream of IL-3
and has been shown to prevent apoptosis after forced ex-
pression in an IL-3–dependent pro-B cell line (21). The
relevance of NF-IL3 in HD is unknown. Notch2 is a trans-
membrane receptor that has been shown to be involved in
cell fate decisions (22). The human Notch2 gene has been
mapped to chromosome 1 at position 1p13-p11, which is a
region of translocations associated with neoplasia (23).
Chromosome 1 has also been linked to the HD phenotype,
since structural rearrangements of chromosome 1 are fre-
quently observed in HD (24). Interestingly, the gene for
Figure 4. Effect of IL-13
treatment on the proliferation of
HD-derived cells. (A–C) KMH2,
HDLM2, and control LCL-HO
cells (105 cells/ml) were treated
with either 20 mg/ml of anti–
IL-13 (A); anti–IL-5 neutralizing
antibodies (B); or the matching
IgGk1 and IgGk2 isotype con-
trols (C). Proliferation was mea-
sured at 24 and 72 h by [3H]thy-
midine incorporation. The y-axis
shows the proliferation of the
treated culture as a percentage of
the untreated control, calculated
as the mean of triplicate samples.
(D–F) Relative proliferation
(percentage of the [3H]thymi-
dine incorporated by the un-
treated control) of HDLM2 cells
48 h after treatment with various
doses of anti–IL-13 antibody or
isotype control (D); a combina-
tion of 20 mg/ml anti–IL-13
with various doses of IL-13 (E);
or various doses of IL-13 alone
(F). For the control, 11,031 cpm
was taken to represent 100%
proliferation. 
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CD30, which was first identified in the HD-derived cell
line L428 (25) and is considered a marker for the disease, is
also located on chromosome 1 at 1p36 (26). CD30 is highly
expressed in lymphoblastoid cells and H/RS cells and has
been shown to promote a Th2 phenotype (27). The possi-
ble roles of NF-IL3 and Notch2 and their relationship to
IL-13 and the CD30 antigen in the pathogenesis of HD
lymphoma require further investigation.
In conclusion, our data combined with recent reports on
the function of IL-13 indicate that IL-13 may be a critical
cytokine in the etiology of HD. We have shown both that
IL-13 is secreted by HD tumor cells and that IL-13 specifi-
cally promotes the proliferation of these cells. Our results
are consistent with a role for IL-13 in the pathogenesis of
the fibrosis, increased IgE production, and bias towards
Th2 cells, all of which are typical of classical HD.
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